After seeing the breakthrough work of scientists and clinicians during the Covid pandemic, it is exciting to work with pharma services companies as they help their clients address other diseases and illnesses and help make treatments widely available for those who might need them.
Healthcare
Pharma Services
Exciting scientific advances have resulted in a new generation of treatments and therapies that in many cases improve or save the lives of patients facing a broad range of health challenges. At the same time, the pharmaceutical value chain has grown increasingly complex. Companies involved in the critical mission of scientific discovery require partners who can help them bring new products to market.
We seek to partner with companies across the entire value chain—supporting R&D, drug discovery, manufacturing, bioprocessing, packaging & logistics, clinical support, commercialization and distribution—to help the pharmaceutical sector deliver lifesaving treatments that result in improved patient outcomes.
The future of Pharma Tech
Data: What are the Use Cases?
Data Driven Advances in Clinical Trials
Clinical Trials: The Evolving Landscape
AI: The Future of Research and Care
AI and Pharma: 5 Use Cases
THL Pharma IT Panel Discussion
What excites us about this ever evolving sector
Red Nucleus Announces Majority Investment from THL Partners
Strategic Investment Will Support Expanded Offerings for Company’s Global Customer Base Industry Veteran Mike Menta to Serve as Chief Executive Officer YARDLEY, PENNSYLVANIA, October 17, 2024/ Red Nucleus ( “the Company”), a leading provider of strategic services across research and development, medical affairs, market access, and learning and development, today announced that it has received a majority
Navigating the Complexities of the Specialty Drug Market
Challenges, Opportunities, and Insights from Asembia’s AXS24 Conference Key Takeaways: The specialty drug market is experiencing rapid growth and there is increasing commercial optimism in the space. There are clear opportunities to streamline drug delivery and improve patient access and adherence. To address the complexities of the specialty drug market —pricing, reimbursement, and access, to name a few
2023 Healthcare Trends and Our Outlook for 2024
Operational Challenges, Patent Cliffs & Biotech Funding Slowdown, and Generative AI Define 2023; Encouraging Prospects Emerge for 2024 Key Takeaways: The healthcare industry experienced a significant transformation in 2023, driven by three defining trends: operational challenges due to staffing shortages and evolving payment models, looming patent cliffs for pharma manufacturers and a biotech funding slowdown that impacted
The Future of Pharmaceuticals: How Technology, Big Data, and AI May Help Speed Drug Development
A Recap of THL’s Pharma Technology Panel | Fall 2023 Key Takeaways: The pharmaceutical industry is undergoing a digital transformation driven by emerging technology, data proliferation, and artificial intelligence (AI). AI is playing a pivotal role in clinical trials by handling complex tasks and analyzing massive health data sets with speed and precision to ultimately improve the efficiency
Megan Preiner Managing DirectorAs we watch the incredible pace of innovation within the pharmaceutical industry, we’re excited to partner with the companies that are enabling these pharma companies across the value spectrum and helping bring medicines and therapies to the public as quickly and efficiently as possible.
Megan Preiner on the Growing Trend of Outsourcing in Pharma Services | Axios
THL’s approach to building strong platforms in this space
Megan Preiner talks investing in a crowded healthcare market | PE Hub
Syneos Health Announces Secondary Offering of Common Stock
RALEIGH, N.C. (GLOBE NEWSWIRE) — Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), a leading biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that affiliates of Thomas H. Lee Partners, L.P. intend to offer for sale in an underwritten secondary offering 6,000,000 shares of
Boosting the go-to-market strategy and accelerating new product development for a pharma services leader
Red Nucleus Announces Majority Investment from THL Partners
Strategic Investment Will Support Expanded Offerings for Company’s Global Customer Base Industry Veteran Mike Menta to Serve as Chief Executive Officer YARDLEY, PENNSYLVANIA, October 17, 2024/ Red Nucleus ( “the Company”), a leading provider of strategic services across research and development, medical affairs, market access, and learning and development, today announced that it has received a majority
Navigating the Complexities of the Specialty Drug Market
Challenges, Opportunities, and Insights from Asembia’s AXS24 Conference Key Takeaways: The specialty drug market is experiencing rapid growth and there is increasing commercial optimism in the space. There are clear opportunities to streamline drug delivery and improve patient access and adherence. To address the complexities of the specialty drug market —pricing, reimbursement, and access, to name a few
2023 Healthcare Trends and Our Outlook for 2024
Operational Challenges, Patent Cliffs & Biotech Funding Slowdown, and Generative AI Define 2023; Encouraging Prospects Emerge for 2024 Key Takeaways: The healthcare industry experienced a significant transformation in 2023, driven by three defining trends: operational challenges due to staffing shortages and evolving payment models, looming patent cliffs for pharma manufacturers and a biotech funding slowdown that impacted
The Future of Pharmaceuticals: How Technology, Big Data, and AI May Help Speed Drug Development
A Recap of THL’s Pharma Technology Panel | Fall 2023 Key Takeaways: The pharmaceutical industry is undergoing a digital transformation driven by emerging technology, data proliferation, and artificial intelligence (AI). AI is playing a pivotal role in clinical trials by handling complex tasks and analyzing massive health data sets with speed and precision to ultimately improve the efficiency
Life sciences, pharma services to dominate health care M&A | Axios
THL’s Josh Nelson speaks with Axios on the Pharma Services Dealmaking Landscape
Megan Preiner on the Growing Trend of Outsourcing in Pharma Services | Axios
THL’s approach to building strong platforms in this space
Megan Preiner talks investing in a crowded healthcare market | PE Hub
Syneos Health Announces Secondary Offering of Common Stock
RALEIGH, N.C. (GLOBE NEWSWIRE) — Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), a leading biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that affiliates of Thomas H. Lee Partners, L.P. intend to offer for sale in an underwritten secondary offering 6,000,000 shares of
INC Research and inVentiv Health to Merge
Creates a Leading Global Biopharmaceutical Solutions Organization with Combined Net Revenue of More Than $3.2 Billion Combined Company Will Be Second Largest Biopharmaceutical Outsourcing Provider, One of the Top 3 Contract Research Organizations and the Largest Contract Commercial Organization by Net Revenue Comprehensive Suite of End-To-End Solutions to Support Development and Commercialization of Biopharmaceutical Compounds and Biologics Complementary
Life sciences, pharma services to dominate health care M&A | Axios
THL’s Josh Nelson speaks with Axios on the Pharma Services Dealmaking Landscape
Megan Preiner on the Growing Trend of Outsourcing in Pharma Services | Axios
THL’s approach to building strong platforms in this space
Megan Preiner talks investing in a crowded healthcare market | PE Hub
Red Nucleus Announces Majority Investment from THL Partners
Strategic Investment Will Support Expanded Offerings for Company’s Global Customer Base Industry Veteran Mike Menta to Serve as Chief Executive Officer YARDLEY, PENNSYLVANIA, October 17, 2024/ Red Nucleus ( “the Company”), a leading provider of strategic services across research and development, medical affairs, market access, and learning and development, today announced that it has received a majority
Syneos Health Announces Secondary Offering of Common Stock
RALEIGH, N.C. (GLOBE NEWSWIRE) — Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), a leading biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that affiliates of Thomas H. Lee Partners, L.P. intend to offer for sale in an underwritten secondary offering 6,000,000 shares of
INC Research and inVentiv Health to Merge
Creates a Leading Global Biopharmaceutical Solutions Organization with Combined Net Revenue of More Than $3.2 Billion Combined Company Will Be Second Largest Biopharmaceutical Outsourcing Provider, One of the Top 3 Contract Research Organizations and the Largest Contract Commercial Organization by Net Revenue Comprehensive Suite of End-To-End Solutions to Support Development and Commercialization of Biopharmaceutical Compounds and Biologics Complementary
Want to learn more?
Let’s explore how we can collaborate with your company.
Contact